TY - JOUR T1 - CVS effects of ▼ canagliflozin JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 15 LP - 15 DO - 10.1136/dtb.2018.2.0582 VL - 56 IS - 2 A2 - , Y1 - 2018/02/01 UR - http://dtb.bmj.com/content/56/2/15.1.abstract N2 - Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been reported to reduce macrovascular complications in people with type 2 diabetes and elevated cardiovascular risk.1 Using data from the same study programme, the authors have assessed the effect of canagliflozin among patients with and without a history of cardiovascular disease (secondary versus primary prevention).2 The study involved two trials that randomly assigned 10,142 participants with type 2 diabetes to canagliflozin or placebo.1, 2 … ER -